Kalvista Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Frazier Life Sciences entities and individuals report significant sales of KalVista Pharmaceuticals common stock over a 60-day period ending May 19, 2026.
NASDAQ
Frazier Life Sciences funds updated their beneficial ownership in KalVista Pharmaceuticals, Inc. to reflect a merger between two of their investment vehicles.
NASDAQ
Frazier Life Sciences funds filed an amended Schedule 13D for KalVista Pharmaceuticals, Inc., clarifying beneficial ownership percentages and attribution.